Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-muscle Invasive Bladder Cancer.

The aim of the study was to demonstrate the most common genetic alterations and evaluate possible targets involving PIK3/AKT/mTOR signaling and DNA damage repair (DDR) pathways for personalized treatment in patients with NMIBC. Alterations of these pathways were observed in 89.5% and 100% of patients, respectively. Among them, BARD1 was more frequently altered in low/intermediate-risk cases, but PARP4 was more frequently affected in intermediate/high-risk patients. The possible target feasibility of BARD1 and PARP4 alterations should be evaluated for personalized treatment using PARP-inhibitors in NMIBC. It is important to detect high tumor mutation burden in patients in terms of immunotherapy.